Ipragliflozin (L-Proline)

Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

Product Specifications

CAS Number

[951382-34-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Ipragliflozin_L-Proline.html

Purity

99.88

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=C([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1CC3=CC(C=CC=C4)=C4S3.O=C(O)[C@H]5NCCC5

Molecular Formula

C26H30FNO7S

Molecular Weight

519.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Imamura M, et al. Discovery of Ipragliflozin (ASP1941) : a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20 (10) :3263-79.|[2]Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341 (3) :692-701.|[3]Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385 (4) :423-36.|[4]Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120 (1) :36-44.|[5]Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715 (1-3) :246-55.